{"id":498961,"date":"2021-05-26T09:03:35","date_gmt":"2021-05-26T13:03:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/"},"modified":"2021-05-26T09:03:35","modified_gmt":"2021-05-26T13:03:35","slug":"rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/","title":{"rendered":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CRANBURY, N.J., May  26, 2021  (GLOBE NEWSWIRE) &#8212;  <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kfau-IJRgxzq3FzJX9vnDl0RMNl4ZwzMbqSFW53E0CJQniBEk03I6Yalkv7gVyEXXlbT7-tVSyLk7-ljDu43xn5hyCXZKjowIRHt0CYU6Gs=\" rel=\"nofollow noopener\" target=\"_blank\">Rafael Pharmaceuticals, Inc.<\/a> (\u201cRafael\u201d or the \u201cCompany\u201d), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kvW_6CEs9B0za6fGwL3Urg_du-HZpqXt11kTfJ2JdwsM6-DMKpq4vQQK1LLfYVUEzBp7dchaAQ8wLidW0JdPdBQDuyLNuyhBuJiWz7iJCkhs-bypcIE-YZ1Lljv3uFsCRWsdqIXkZmAn97vKIJQWQCOsqr956EdLeA6eDG5hjJU=\" rel=\"nofollow noopener\" target=\"_blank\">American Society of Clinical Oncology (ASCO) Annual Meeting<\/a>, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer.<\/p>\n<p>\n        <br \/> \u201cWe are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress,\u201d said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. \u201cThe data continues to show us hope for the future, with our continued commitment to patients at the forefront.\u201d<\/p>\n<p>\n        <br \/>\n        <b>Presentation Details:<\/b><br \/>\n        <br \/>Title:\u00a0 Abstract #TPS4158: A multicenter, randomized phase 1b\/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)<br \/>Date: June 4, 2021<br \/>Time: 8:00 a.m. ET<br \/>Location: ASCO Meeting Library<\/p>\n<p>\n        <br \/> Title:\u00a0 Abstract #TPS4176: A phase II open-label study of CPI-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.<br \/>Date: June 4, 2021<br \/>Time: 8:00 a.m. ET<br \/>Location: ASCO Meeting Library<\/p>\n<p>\n        <br \/> \u201cIt\u2019s an honor to be able to present our ongoing research in pancreatic cancer at one of the most renowned meetings in clinical oncology. As pancreatic cancer remains a challenge for patients and clinicians, each presentation is an opportunity to share the potential for devimistat as a future treatment option,\u201d said David L. Bajor M.D., Assistant Professor, Seidman Cancer Center, University Hospitals Cleveland, Case Comprehensive Cancer Center.\u00a0<\/p>\n<p>\n        <br \/> \u201cAdvanced biliary cancer remains a challenge for patients and clinicians and it is crucial to continue to investigate promising novel agents, such as devimistat in this rare cancer,\u201d said Vaibhav Sahai, MBBS, M.S., Principal Investigator, University of Michigan.\u00a0<\/p>\n<p>\n        <br \/>\n        <b>About CPI-613\u00ae (devimistat)\u00a0<\/b><br \/>\n        <br \/>CPI-613\u00ae (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Devimistat is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells. Devimistat substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This synergy allows for potential combinations of devimistat with lower doses of these generally toxic drugs to be more effective with lower patient\u2019s side effects. Combination with devimistat represent a diverse range of opportunities to substantially improve patient\u2019s benefit in many different cancers. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal Phase 3 clinical trials in pancreatic cancer (AVENGER 500) and acute myeloid leukemia (ARMADA 2000) and has designated devimistat as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma and Burkitt\u2019s lymphoma. The EMA has granted orphan drug designation to devimistat for pancreatic cancer and acute myeloid leukemia.<\/p>\n<p>\n        <br \/>\n        <b>About Rafael Pharmaceuticals, Inc.<\/b><br \/>\n        <br \/>Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Rafael Pharmaceuticals\u2019 lead compound, CPI-613\u00ae (devimistat), is a highly selective, well-tolerated and effective anti-cancer agent that is being evaluated in ongoing and completed Phase 1, 2 and 3 clinical trials. Devimistat has been granted orphan drug status by the FDA for the treatment of pancreatic cancer, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Burkitt\u2019s, peripheral T-cell lymphomas and soft tissue sarcoma. The Company&#8217;s investors include Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6iijd3yhgd3wV4aT1hfNOt4AX8j9ErTEZo7Tcft-B1_8PWkSz_68wh6QFkIULnZ8KklzjoCdqRcub6AZ-cIrT0fabVa78s4kDBg2Xl8u-ZY=\" rel=\"nofollow noopener\" target=\"_blank\">www.rafaelpharma.com<\/a>.<\/p>\n<p>\n        <br \/>\n        <b>Safe Harbor Statement<\/b><br \/>\n        <br \/>This press release contains forward-looking statements. These statements relate to future events or the company\u2019s future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221; or &#8220;continue&#8221;, the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. <br \/> In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. <\/p>\n<p>\n        \n      <\/p>\n<p> ###<\/p>\n<p>\n        \n      <\/p>\n<p>\n        <b>Rafael Media Contact:<\/b><br \/>\n        <br \/>Diana Cleinmark<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZRgR7ifdrjwEYpKtp18hdM_TM2Ky5A3T7XdyC8ax1kUITO1RHLMNB75jfNFgC-vQzl9dFnifxXf5nigGooTQygYxvBNvhUANT9Kctr1tcX0=\" rel=\"nofollow noopener\" target=\"_blank\">rafael@antennagroup.com<\/a>\u00a0<br \/>(408) 713-1216   <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f976652c-f428-434b-b604-03ae6dbf877c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) &#8212; Rafael Pharmaceuticals, Inc. (\u201cRafael\u201d or the \u201cCompany\u201d), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer. \u201cWe are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress,\u201d said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. \u201cThe data continues to show us hope for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-498961","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) &#8212; Rafael Pharmaceuticals, Inc. (\u201cRafael\u201d or the \u201cCompany\u201d), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer. \u201cWe are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress,\u201d said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. \u201cThe data continues to show us hope for &hellip; Continue reading &quot;Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T13:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program\",\"datePublished\":\"2021-05-26T13:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/\"},\"wordCount\":827,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/\",\"name\":\"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=\",\"datePublished\":\"2021-05-26T13:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/","og_locale":"en_US","og_type":"article","og_title":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program - Market Newsdesk","og_description":"CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) &#8212; Rafael Pharmaceuticals, Inc. (\u201cRafael\u201d or the \u201cCompany\u201d), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer. \u201cWe are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress,\u201d said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. \u201cThe data continues to show us hope for &hellip; Continue reading \"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-26T13:03:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program","datePublished":"2021-05-26T13:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/"},"wordCount":827,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/","name":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=","datePublished":"2021-05-26T13:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0Mjk1OCM0MjAxNjc1IzIwMjc2ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rafael-pharmaceuticals-to-present-new-pancreatic-cancer-and-biliary-tract-cancer-data-featuring-cpi-613-devimistat-at-the-american-society-of-clinical-oncology-asco-2021-virtual-scientific-p\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=498961"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=498961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=498961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=498961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}